Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD) | The Manila Times
**media[1042227]**Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHD
Ähnliche Seiten
Cellenkos, Inc.: Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
https://www.finanznachrichten.de/nachrichten-2026-05/68389742-cellenkos-inc-cellenkos-announces-fda-clearance-of-investigational-new-drug-ind-application-for-phase-1b-2a-trial-of-ck0802-in-steroid-refractor-008.htm
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors | The Manila Times
https://www.manilatimes.net/2026/05/08/tmt-newswire/pr-newswire/harbour-biomed-announces-us-fda-ind-clearance-for-hbm7004-for-the-treatment-of-advanced-solid-tumors/2339316Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis | The ...
https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis/2305475World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application | The Manila Times
https://www.manilatimes.net/2026/05/09/tmt-newswire/pr-newswire/worlds-first-mabwells-9mw5211-receives-fda-clearance-for-clinical-trial-application/2339851Roche Announces Filing Acceptance Of New Drug Application For Giredestrant
https://www.finanznachrichten.de/nachrichten-2026-02/67747815-roche-announces-filing-acceptance-of-new-drug-application-for-giredestrant-020.htm